Almirante continues its momentum and maintains its love affair with the markets

BarcelonaThe pharmaceutical company Almirall has reached the halfway point of the financial year, maintaining the good pace from the beginning of the year: although the first quarter shot up profits to 21.6 million, Almost triple that of the first three months of 2024, in the first half of the year as a whole the company has earned €26.5 million, 72.1% more than from January to June of last year.

These results, which the firm announced this Friday, have boosted its stock market gains by more than 5% in the early hours, leading it momentarily to lead the continuous market, which integrates the Barcelona, Madrid, Valencia, and Bilbao stock exchanges into a single stock market. However, the euphoria did not last long: by midday, Almirall was down 1.49% and now, around 2:00 p.m., it remains in positive territory. If the day ends like this, the company owned by the Gallardo family, which holds 60.1% of the capital, would maintain this year's love affair with the markets, where it has accumulated growth of more than 31%. The Norbel group, the holding company of the family that also owns the listed company Rovi, has a 5% stake, so the free float, that is, the shares traded on the stock exchange, represent only 35% of total capital.

The increase in sales, which have brought in €560.5 million to the company in these first six months, has been driven mainly by the dermatology business in Europe, the most important division and market for Almirall, as it represents more than half of the company's total revenue—the remainder is the area of total income. Only €49 million of those €560 million come from the United States and the rest of the world, with just over €24 million in revenue each.

The dermatology drugs that have driven the most growth in these results are Ilumetrio and Ebglyss. The former is indicated for patients with psoriasis and the latter for atopic dermatitis. Almirall is now in the middle of the investment phase, with four clinical trials scheduled to begin Phase II—which consists of medical tests with patients with the disease being treated—to develop treatments for dermatological diseases. It will invest between 60 and 80 million euros this year..

"Our strong performance gives us the confidence to achieve our long-term goal: to be a leader in medical dermatology. This, in turn, will allow us to help more patients with more relevant treatments [...]. In addition, we continue to invest in R&D to further boost our product portfolio," explained the company's CEO.